Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003040 | 0.92 | ADORA1 (0.56) | ADORA1SLC6A3 | |
| SCHEMBL12376530 | 0.91 | ADORA1 (0.59) | ADORA1SLC6A3 | |
| SCHEMBL12376496 | 0.86 | ADORA1 (0.52) | ADORA1SLC6A3 | |
| SCHEMBL8001636 | 0.85 | ADORA1 (0.51) | ADORA1SLC6A3 | |
| SCHEMBL7999946 | 0.83 | ADORA1 (0.49) | ADORA1SLC6A3 | |
| SCHEMBL7998996 | 0.83 | ADORA1 (0.51) | ADORA1SLC6A3RET | |
| SCHEMBL8005051 | 0.82 | ADORA1 (0.70) | ADORA1SLC6A3RET | |
| SCHEMBL382420 | 0.82 | ADORA1 (0.71) | ADORA1SLC6A3 | |
| SCHEMBL1177766 | 0.82 | ADORA1 (0.84) | ADORA1SLC6A3RET | |
| SCHEMBL2282177 | 0.81 | ADORA1 (0.73) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274299-B1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF FOR TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-8426602-B2 | Heteroaryl-substituted dicyanopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-25 | — | — | US | disclosed |
| WO-2009112155-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF FOR TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AG (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207698-A1 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE | QDPR, TNNI3, SDHA | ADORA1 3151/4885SLC6A3 1742/4885RET 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.